JohnHo personal page - To The Moon

JohnHo

JohnHo

No personal profile

16Follow

0Followers

0Topic

0Badge

2021-03-15

Comment me

AMC jumps about 18% as it plans to open all California locations

2021-03-16

Comment here

Netflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.

2021-03-01

Good

Sorry, the original content has been removed

2021-03-24

Comment here

AstraZeneca to publish full trial data after U.S. rebuke

2021-03-10

Great!

Sorry, the original content has been removed

2022-02-09

Nice

7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market

2021-04-02

Down more

Sorry, the original content has been removed

2021-03-24

Good

AstraZeneca to publish full trial data after U.S. rebuke

2021-03-11

Comment here

Cathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3567067505165206","uuid":"3567067505165206","gmtCreate":1604377249306,"gmtModify":1704447495447,"name":"JohnHo","pinyin":"johnho","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":16,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.21","exceedPercentage":"80.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.13","exceedPercentage":"60.39%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9013016453,"gmtCreate":1648652481115,"gmtModify":1676534372126,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Celebrating&nbsp;500days in Tiger!","listText":"Celebrating&nbsp;500days in Tiger!","text":"Celebrating 500days in Tiger!","images":[{"img":"https://community-static.tradeup.com/news/9046067db6bc5292c6019fa8f5722136","width":"1440","height":"2056"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013016453","isVote":1,"tweetType":1,"viewCount":2865,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9096176622,"gmtCreate":1644341299934,"gmtModify":1676533914682,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096176622","repostId":"1153281093","repostType":4,"repost":{"id":"1153281093","kind":"news","pubTimestamp":1644333754,"share":"https://ttm.financial/m/news/1153281093?lang=en_US&edition=fundamental","pubTime":"2022-02-08 23:22","market":"us","language":"en","title":"7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1153281093","media":"InvestorPlace","summary":"Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out ","content":"<div>\n<p>Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out ...</p>\n\n<a href=\"https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-08 23:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out ...</p>\n\n<a href=\"https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚","AAPL":"苹果","LMT":"洛克希德马丁","PFE":"辉瑞","WMT":"沃尔玛","INTC":"英特尔","COST":"好市多"},"source_url":"https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153281093","content_text":"Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out to be theworst start to the yearin over a decade. The incredible volatility in the market is attributable to multiple macro-economic factors, which have investors scrambling to safe-haven investments. Hence, it’s best to add a few blue-chip stocks to your portfolio to minimize risks.Investors are caught amid a perfect storm in the stock market. The Fed’s hawkish policies, the rising inflation, geopolitical tensions, and the pandemic’s grip over the world have pulverized market returns. Moreover, the Cboe Volatility Index is up over 70% year-to-date.Hence, in the current scenario, it’s best to bet on blue-chip stocks with a long track record of top and bottom-line growth. Additionally, these companies also have strong track records of growing shareholder rewards despite the challenges presented by the market.Let’s now look at seven of the most attractive blue-chip stocks to buy at this time.Apple Walmart Exxon Mobil Pfizer Intel Corporation Costco Wholesale Lockheed Martin Apple Source: dennizn / Shutterstock.comApple has had a phenomenal run in the past couple of years,crossing $3 trillion in market capitalizationlast month.Despite the challenges, AAPL stock has generated solid returns over the past year, driven by staggering growth across all its business segments. The iPhone market boasts a most innovative product lineup with a loyal customer base.The free cash flow juggernaut boasts a levered FCF growth of 20%. Its cash flow expansion rate is stunning and will continue to grow with its top-line. Revenue growth is over 28.5% on a year-over-year basis, comfortably ahead of its 5-year average.Apple has done incredibly well to leverage several secular megatrends, including 5G, the metaverse, streaming, EVs, and whatnot. Hence, if there’s one blue-chip to buy, you’d want to invest in AAPL.Walmart Source: fotomak / Shutterstock.comWalmart has proven time and being that it’s the template for its sector.The retail giant has dominated the brick-and-mortar sector and has significantly expanded its eCommerce wing. Though the pandemic has slightly altered its growth trajectory, its long-term case remains firmly intact.During the first nine months of fiscal 2022, Walmart’s $416 billion sales increased by 3% compared with the prior-year period. However, its net income slid 35%.Nevertheless, it projects optimism and expects a 6% growth in comparable sales for the year. It has also raised earnings guidancefor the year by 20 cents to $6.40 per share.Looking ahead, the company will continue improving its eCommerce productivity and return to winning ways with its brick-and-mortar business.Exxon Mobil Source: Jonathan Weiss / Shutterstock.comExxon Mobil grew its earnings at an astounding pace last year. Year-over-year growth in its EBITDA is at a spectacular 75%.The oil and gas giant also is ramping up capital expenditure to explore a clean energy future and offers an attractive 4.37% dividend yield with remarkable consistency.Exxon Mobil saw a massive improvement in its top-line due to the robust crude oil prices last year. Revenues grew at a rapid clip while it managed to reduce debt levels by a colossal $20 billion.It improved its breakdown significantly by getting a better handle on costs. Additionally, it could spend a truckload of cash on expanding its low carbon efforts.With an impressive asset portfolio, outstanding financials and a tremendous outlook ahead, XOM stock is in a fantastic position to grow for the foreseeable future.Pfizer Source: photobyphm / Shutterstock.comPharmaceutical giant Pfizer has raked in billions from coronavirus vaccines sales, and its vaccines continue to be in high demand with the emergence of new variants of the virus.Vaccine salescontributed $36 billionin sales last year, doubling revenues for the company from 2020.Pfizer has demonstrated superb execution and scaling capacity, making it a top vaccine manufacturer in the west.Moreover, the pandemic is expected to be endemic, and the vaccine maker can still rake in plenty of moolah for the foreseeable future.It is also developing new products such as an oral antiviral tablet to treat early-stage Covid 19 symptoms. Hence, PFE stock still has a strong growth runway ahead.Intel Corporation Intel is one of the most powerful tech giants globally, with a market cap of over $180 billion.It is a household name in the semi-conductor space possessing superior manufacturing capabilities. In recent years, though, it has ceded a considerable amount of market share to its peers.It now looks as if Intel has a clear road to claw back its market share and expand into other profitable verticals.As we advance, the company will be looking to source some of its components from TSMC(NYSE:TSM) in speeding up chip development.It also plans to set up its personal chip foundry service, and its acquisition of autonomousdriving solutions provider Mobileyecould potentially unlock $50 billion in value.Also, Intel has the organic resources to pursue its developments plans, as it continues to generate unbelievable cash flows.Costco Wholesale Source: ARTYOORAN / Shutterstock.comRetail giant Costco has been one of the most consistent performers in its sector.Last year, the company grew its top and bottom lines by double-digits by 17.5% and 25.1%, respectively.With its water-tight balance sheet and unique competitive advantages, COST stock has been one of the top growth stocks over the years.Costco added 22 new warehouses to expand its outreach and more than 6 million new membersto its subscription service, with a roughly 92% renewal rate.Though its membership fees represent a small portion of sales, they contribute immensely to expanding profitability margins.The ability to offer low prices fuels membership growth. Hence, there’s plenty to love about COST stock as a long-term bet.Lockheed Martin Source: Ken Wolter / Shutterstock.comLockheed Martin is the leading defense contractor for the United States government.It has become a juggernaut in the space by being a provider of the F-35 JSF program.The company has been a robust performer with double-digit average revenue growth over the past five years while generating a monstrous 53% return during the same period.Last year,the company delivered 142 F-35 jetsto its customers, beating its previous guidance of 139 deliveries. Moreover, it expects to nail its production goal of 151-153 jets next year. The stellar performance has led to a healthy increase in its FCF margin to 7.3%. On top of that, it’s maintained its reputation as a top income stock in the space, with a 2.9% yield and a payout ratio of over 35%.","news_type":1,"symbols_score_info":{"WMT":0.9,"AAPL":0.9,"INTC":0.9,"XOM":0.9,"COST":0.9,"LMT":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098223850,"gmtCreate":1644151452071,"gmtModify":1676533894557,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Xilimx amd stronk!!","listText":"Xilimx amd stronk!!","text":"Xilimx amd stronk!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098223850","isVote":1,"tweetType":1,"viewCount":2362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098223348,"gmtCreate":1644151415001,"gmtModify":1676533894549,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Join&nbsp;","listText":"Join&nbsp;","text":"Join","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098223348","repostId":"9004448317","repostType":1,"repost":{"id":9004448317,"gmtCreate":1642676525258,"gmtModify":1676533734534,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"Join Tiger Ski Championship, Win a Bonus of Up to USD 2022","htmlText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","listText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","text":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: Click to Join the Game","images":[{"img":"https://static.tigerbbs.com/a7b44fa056439fb4010fa55e163d27c3","width":"750","height":"1726"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004448317","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186401032,"gmtCreate":1623515789526,"gmtModify":1704205406890,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186401032","repostId":"1148565686","repostType":4,"repost":{"id":"1148565686","kind":"news","pubTimestamp":1623514343,"share":"https://ttm.financial/m/news/1148565686?lang=en_US&edition=fundamental","pubTime":"2021-06-13 00:12","market":"us","language":"en","title":"This Is The Ultimate Warren Buffett Stock, But Should You Buy It?","url":"https://stock-news.laohu8.com/highlight/detail?id=1148565686","media":"investors","summary":"Warren Buffett is widely regarded as one of the greatest investors of all time. One way to share in his success is to invest in his firm,Berkshire Hathaway. Berkshire stock has cleared a buy zone, but is it a good buy for you now?Let's take a close look at the fundamental and technical performance of the ultimate Warren Buffett stock.Berkshire Hathaway is a conglomerate that owns some of America's most famous firms. It wholly owns the likes of Geico, Duracell, Dairy Queen, Fruit of the Loom and ","content":"<p>Warren Buffett is widely regarded as one of the greatest investors of all time. One way to share in his success is to invest in his firm,<b>Berkshire Hathaway</b>(BRKB). Berkshire stock has cleared a buy zone, but is it a good buy for you now? Let's take a close look at the fundamental and technical performance of the ultimate Warren Buffett stock.</p>\n<p>Berkshire Hathaway is a conglomerate that owns some of America's most famous firms. It wholly owns the likes of Geico, Duracell, Dairy Queen, Fruit of the Loom and railroad operator BNSF.</p>\n<p>Berkshire Hathaway is perhaps more famous for serving as an investment vehicle for Warren Buffett and his top lieutenant, Charlie Munger. Following their value investing philosophy,the company owns huge stakesin&nbsp;<b>American Express</b>(AXP),&nbsp;<b>Coca-Cola</b>(KO) and other heavy hitters.</p>\n<p>But the definition of a Warren Buffett stock has evolved in recent years.&nbsp;Warren Buffett became a big investor in airlines such as<b>Delta Air Lines</b>(DAL). But he was left to rue his decision to go against his own long-held views about that industry's lack of profitability. The move blew up in his face as airline stocks were decimated due to the global coronavirus pandemic.</p>\n<p>Under investment managers Todd Combs and Ted Weschler, Berkshire Hathaway has been increasingly sinking money into tech. It's taken large positions in established giants like<b>Apple</b>(AAPL), as well as younger companies like Brazilian payments company<b>StoneCo</b>(STNE) and new software IPO<b>Snowflake</b>(SNOW). Berkshire also snapped up a stake in<b>Amazon.com</b>(AMZN).</p>\n<p><b>Warren Buffett Anoints Successor</b></p>\n<p>One of the biggest questions around the future of Berkshire Hathaway in recent years was who would take over the mantle of CEO from Buffett.</p>\n<p>The Oracle of Omahahas finally gave the answer. He said Greg Abel, who runs the noninsurance businesses, will take over in his stead.</p>\n<p>\"The directors are in agreement that if something were to happen to me tonight, it would be Greg who'd take over tomorrow morning,\" the legendary investor told CNBC.</p>\n<p>Berkshire's Vice Chairman Charlie Munger dropped a massive hint during the&nbsp;company's annual meeting in Los Angeles, mentioning that \"Greg will keep the culture.\"</p>\n<p>Abel, 58, has been a Berkshire vice chairman since 2018, and had long been viewed by analysts as a possible successor. The Canadian is chairman and CEO of Berkshire Hathaway Energy. He has also been vice chairman of Berkshire's noninsurance operations since January 2018.</p>\n<p><b>Buffett Snaps Up Berkshire Stock</b></p>\n<p>Berkshire Hathaway revealed in its Q1 earnings report that it had snapped up $6.6 billion more of its shares. It comesafter a record $27.4 billion in repurchaseslast year. This was down from the $9 billion in stock it had purchased in each of the previous two quarters however.</p>\n<p>After historically shying away from repurchases, Berkshire Hathaway stock has become one of Buffett's top purchases.&nbsp;Berkshire's aggressive share repurchases contrasts with the M&amp;A deals spun by the investor during and after the 2008 financial crash.</p>\n<p>While he has historically been reluctant to splurge on stock repurchases, he explained his change of heart in his latest annual letter to shareholders.</p>\n<p>\"The math of repurchases grinds away slowly, but can be powerful over time,\" he wrote. \"The process offers a simple way for investors to own an ever-expanding portion of exceptional businesses.\"</p>\n<p>Berkshire loosened rules for Buffett to buy back shares in 2018. With Berkshire steadfastly cautious on M&amp;A in recent years, investors have been clamoring for more repurchases.</p>\n<p><b>Berkshire Hathaway Tweaks Portfolio</b></p>\n<p>Warren Buffett took a huge stake in<b>Verizon</b>(VZ) stock while dumping JPMorgan (JPM) stock entirely, according to thefirm's latest regulatory filing.</p>\n<p>Its new Verizon stake is massive, with Berkshire paying $8.62 billion for 147 million shares. It now accounts for 3% of the portfolio, making it the No. 6 stock by number of shares held.</p>\n<p>Buffett also opened new stakes in<b>Chevron</b>(CVX),<b>Marsh &amp; McLennan</b>(MMC) and<b>EW Scripps</b>(SSP) in Q4.</p>\n<p>Berkshire dumped entirely<b>Pfizer</b>(PFE),<b>JPMorgan Chase</b>(JPM),<b>Barrick Gold</b>(GOLD),<b>M&amp;T Bank</b>(MTB) and<b>PNC Financial</b>(PNC).</p>\n<p>The conglomerate grew stakes by 117% in<b>T-Mobile</b>(TMUS), 34% in<b>Kroger</b>(KR), 28% in<b>Merck</b>(MRK), 20% in<b>AbbVie</b>(ABBV), 11% in<b>Bristol-Myers Squibb</b>(BMY), and 1% in<b>RH</b>(RH).</p>\n<p>Buffett cut Berkshire's stake in Apple stock by 6%. It remains the No. 1 stock in his portfolio by market value and No. 2 stock by number of shares held, at 10.6% of the portfolio. He kept an Amazon stake steady.</p>\n<p>During its most recent earnings report, the firm revealed it had sold $6.45 billion in stock in Q1 and bought $2.57 billion in stock.</p>\n<p><b>Warren Buffett Funds Media Deal</b></p>\n<p>Berkshire Hathaway is a key backer in a deal disclosed Sept. 24 that will see TV station owner<b>E.W. Scripps</b>(SSP) purchase privately held cable network ION Media for $2.65 billion. The latter firm's flagship, ION Television, is a top 5-ranked U.S. general entertainment network.</p>\n<p>Warren Buffett's firm is snapping up $600 million of Scripps preferred shares to help fund the deal. Scripps stock surged on on the news.</p>\n<p>Berkshire will also receive a warrant that allows it to snap up up to 23.1 million more shares at a price of $13. This adds up to an additional investment of $300 million. Scripps' common shares currently trade at more than 21 each.</p>\n<p><b>Berkshire Hathaway Coronavirus Exposure</b></p>\n<p>As well as its status as an investment vehicle, Berkshire Hathaway is a conglomerate in its own right. It has interests in segments such as railroads, utilities and energy.</p>\n<p>Those sectors, along with other \"real economy\" companies that are Warren Buffett staples, have been hard hit by the coronavirus shutdowns and massive economic contraction. However they should benefit as the economy opens up again.</p>\n<p>Berkshire owns Geico, the No. 2 U.S. auto insurer after State Farm. Currently, states such as California are ordering insurers to give partial credits or refunds of premiums in lines such as private passenger automobile insurance.</p>\n<p>Berkshire also owns BNSF Railway Company, the largest freight railroad network in North America. Rail operators such as<b>Union Pacific</b>(UNP) and<b>CSX</b>(CSX) have seen business suffer during the pandemic. But rail operators and other transportation companies are seeing business pick up again.</p>\n<p>Other wholly owned businesses such as Dairy Queen and multilevel marketing company Pampered Chef also struggled during coronavirus restrictions, though those are easing.</p>\n<p><b>Warren Buffett's Big Gas Bill</b></p>\n<p>Warren Buffett has been criticized for the size of his cash pile. But last July he madehis biggest acquisition in yearswith a $10 billion deal for<b>Dominion Energy</b>'s (D) assets.</p>\n<p>Berkshire seized the chance to secure Dominion's gas pipeline network after the utility giant and<b>Duke Energy</b>(DUK) unexpectedly aborted plans to build the Atlantic Coast Pipeline.</p>\n<p>Berkshire Hathaway Energy will buy about 7,700 miles of natural gas transmission pipelines and 900 billion cubic feet of gas storage. The all-cash deal includes $4 billion of equity and $5.7 billion of debt. It's set to close in the fourth quarter.</p>\n<p>\"We are very proud to be adding such a great portfolio of natural gas assets to our already strong energy business,\" Buffett said in a statement.</p>\n<p>Energy has been doing well so far in 2021. For example, the Vanguard Energy ETF (VDE) is up almost 40% since the start of the year.</p>\n<p><b>Berkshire Hathaway Stock Technical Analysis</b></p>\n<p>Berkshire Hathaway stock is in a profit-taking zone after breaking out of aflat base, according toMarketSmith analysis. Theideal buy pointwas 235.09. Shares offered a follow-on buy point around 246 in late March after a test of the 10-week line, but are extended from here as well.</p>\n<p>It could go on to form a new base with an entry point of 295.18, it can continue to consolidate below this level.</p>\n<p>BRKB stock is well clear after pulling away from its50-day moving average, though the key technical benchmark is beginning to catch up. This is a positive sign for holders of the stock.</p>\n<p>Therelative strength lineof Berkshire Hathaway stock has been slippi8ng somewhat of late after a spell of progress that kicked off in mid-March. BRKB stock is outperforming in 2021. So far this year, it is up around 23%, which beats the broader S&amp;P 500's return of almost 13%.</p>\n<p>ItsIBD Composite Ratingnow sits at 69 out of 99. This is not ideal, but puts it in the top 31% of stocks tracked overall.</p>\n<p>Earnings are&nbsp; improving, with EPS accelerating for the past two quarters. However earnings have only grown by an average of 5% over the past three quarters, with coronavirus pandemic lockdowns having an impact.&nbsp;The CAN SLIM systemrecommends investors look for companies with average EPS growth of at least 25% over this time period.</p>\n<p>Wall Street is becoming more optimistic for Berkshire Hathaway earnings growth going forward. Analysts are projecting annual earnings will rise 24% 2021, before moderating to 7% growth in 2022.</p>\n<p><b>Warren Buffett Recommendation</b></p>\n<p>Berkshire stock had been lagging the S&amp;P 500 index since the end of 2018. Before that, BRKB stock at best moved with the market for a decade. An investor could have bought an index fund or ETF like the SPDR S&amp;P 500 ETF (SPY), and generated similar or higher returns with less stock-specific risk.</p>\n<p>\"In my view, for most people, the best thing to do is owning the S&amp;P 500 index fund, Buffett himself previously said at a Berkshire annual meeting. \"If you bet on America and sustain that position for decades, you'd do far better than buying Treasury securities, or far better than following people. Perhaps with a bias, I don't believe anyone knows what the market is going to do tomorrow, next week, next month, next year.\"</p>\n<p>Nevertheless, BRKB stock has been outperforming the S&amp;P 500 so far this year. It could now finally be set for a decent period of outperformance.</p>\n<p><b>Berkshire Hathaway Earnings Improve</b></p>\n<p>Berkshire Hathaway earnings per share popped 27% in Q1, rising to $3.05. This was well clear of analyst views for EPS of $2.57. Its operating profit, which excludes some investment results, came in at $7 billion.</p>\n<p>The conglomerate's total revenue came in at $64.6 billion last quarter, which was also more than analysts expected.</p>\n<p>The firm's wheeling and dealing on the stock market also saw the firm turn in good gains, increasing approximately $4.69 billion last quarter. However the firm stresses that gains and losses in any particular quarter are \"usually meaningless.\" This fits in with Buffett's longer-term investment philosophy.</p>\n<p><b>Buffett's Cash Mountain Still Mighty</b></p>\n<p>Berkshire's cash pile grew to $145.4 billion in Q1 from $138.3 billion in Q4. It is creeping back up to record level it reached in the third quarter of last year. This has raised expectations that Buffett would make a big acquisition, but he has preferred to sit on the sidelines amid spiraling stock prices.</p>\n<p>Having such a large supply of cash protects the Warren Buffett stock during tough times. It also mean Berkshire Hathaway is able to deploy capital when desirable businesses become available for purchase.</p>\n<p>The more aggressive buying of Berkshire's own shares of late contrasts with Buffett's deals during and after the Great Recession. This indicates he believes that the latest economic downturn and recovery, so far, offer none of the bargains he has historically pounced on.</p>\n<p><b>Analyst Backs Berkshire Stock</b></p>\n<p>CFRA analyst Catherine Seifert is rating BRKB stock as a hold with a 295 price target. She pointed out the mixed nature of the firm's recent earnings report.</p>\n<p>\"Results reflected a doubling of underwriting profits and 12% higher rail/energy/utility profits, despite 13% lower in investment income,\" she said in a May 3 research note. \"We applaud the 33% rise in energy revenues amid contributions from an acquisition, but rail revenues declined fractionally and insurance premium growth of 4.3% lagged peers.</p>\n<p>Nevertheless, she said the shares are currently \"fairly valued versus historical levels.\" The analyst also believes there could be changes afoot once he firm's legendary CEO steps down.</p>\n<p>\"We are disappointed climate change and diversity initiatives failed to be approved at the annual meeting, and think this increases the likelihood of activism in a post-Buffet era,\" she said.</p>\n<p><b>Difference Between BRKA Stock And BRKB Stock</b></p>\n<p>The most obvious difference between Berkshire Hathaway's A class and B class shares is the price. While — at over 200 a share — BRKB stock may be considered relatively expensive, BRKA stock is the most expensive on the market, currently trading near $430,000 a share.</p>\n<p>Warren Buffett decided to introduce the BRKB shares to allow investors to purchase stock directly. Big demand for Berkshire Hathaway stock forced less-moneyed players to plow cash into unit trusts or mutual funds that mirrored his company's holdings.</p>\n<p><b>Berkshire Hathaway Today</b></p>\n<p>Berkshire Hathaway operates in four main sectors.</p>\n<p>Its insurance group is one of its biggest cash cows. One of the most famous jewels in the crown is Geico. Other parts of this business include multinational property/casualty and life/health reinsurance company General Re and Berkshire Hathaway Reinsurance Group. The latter underwrites excess-of-loss reinsurance and quota-share coverage globally.</p>\n<p>Insurance operations are a big reason why Berkshire Hathaway earnings can be lumpy.</p>\n<p>Its Regulated Utility Business group includes Berkshire Hathaway Energy, formerly known as MidAmerican Energy. It also includes railway services arm BNSF, North America's largest freight railroad network.</p>\n<p>Meanwhile, the Manufacturing, Service &amp; Retailing group includes Acme Building Brands, Fruit of the Loom and Justin Brands. The likes of Buffalo News, Business Wire, Dairy Queen and NetJets fall under the service subsector. Retailers include See's Candies, Ben Bridge Jeweler, Helzberg Diamond Shops and Star Furniture.</p>\n<p>Finally, the Finance &amp; Financial Products segment includes: Hathaway Credit Corporation, transportation equipment and furniture leasing specialists XTRA and CORT, and BH Finance whose main interest is in proprietary investing strategies.</p>\n<p><b>Is Berkshire Hathaway Stock A Buy Now?</b></p>\n<p>While Berkshire Hathaway stock has been lagging the S&amp;P 500 index since late 2018, it has been handily outperforming in 2021. However, Berkshire stock is now well clear of its most recent buy zone. Investors keen on the stock could add it to their watchlist, and wait for a new buying opportunity to emerge.</p>\n<p>While its Composite Rating is still not up to scratch, it has improved on this front as well. This makes it an option worth watching for investors seeking to add to their portfolio a well established stock with a diversified portfolio of businesses.</p>\n<p>However, it is worth remember that, after a late-2018 burst, Berkshire Hathaway earnings growth has been modest and uneven. While Wall Street sees solid EPS growth ahead for Berkshire in 2021 and 2022, it still remains shy of the rates sought by CAN SLIM investors.</p>\n<p>Bottom line: Berkshire Hathaway stock is not a buy at the moment. Those interested in buying the ultimate Warren Buffett stock should add it to their watchlist, and wait to see if it forms a new base.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Is The Ultimate Warren Buffett Stock, But Should You Buy It?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Is The Ultimate Warren Buffett Stock, But Should You Buy It?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 00:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/research/berkshire-hathaway-stock-buy-now-warren-buffett-stock/?src=A00220><strong>investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett is widely regarded as one of the greatest investors of all time. One way to share in his success is to invest in his firm,Berkshire Hathaway(BRKB). Berkshire stock has cleared a buy ...</p>\n\n<a href=\"https://www.investors.com/research/berkshire-hathaway-stock-buy-now-warren-buffett-stock/?src=A00220\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","BRK.B":"伯克希尔B"},"source_url":"https://www.investors.com/research/berkshire-hathaway-stock-buy-now-warren-buffett-stock/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148565686","content_text":"Warren Buffett is widely regarded as one of the greatest investors of all time. One way to share in his success is to invest in his firm,Berkshire Hathaway(BRKB). Berkshire stock has cleared a buy zone, but is it a good buy for you now? Let's take a close look at the fundamental and technical performance of the ultimate Warren Buffett stock.\nBerkshire Hathaway is a conglomerate that owns some of America's most famous firms. It wholly owns the likes of Geico, Duracell, Dairy Queen, Fruit of the Loom and railroad operator BNSF.\nBerkshire Hathaway is perhaps more famous for serving as an investment vehicle for Warren Buffett and his top lieutenant, Charlie Munger. Following their value investing philosophy,the company owns huge stakesin American Express(AXP), Coca-Cola(KO) and other heavy hitters.\nBut the definition of a Warren Buffett stock has evolved in recent years. Warren Buffett became a big investor in airlines such asDelta Air Lines(DAL). But he was left to rue his decision to go against his own long-held views about that industry's lack of profitability. The move blew up in his face as airline stocks were decimated due to the global coronavirus pandemic.\nUnder investment managers Todd Combs and Ted Weschler, Berkshire Hathaway has been increasingly sinking money into tech. It's taken large positions in established giants likeApple(AAPL), as well as younger companies like Brazilian payments companyStoneCo(STNE) and new software IPOSnowflake(SNOW). Berkshire also snapped up a stake inAmazon.com(AMZN).\nWarren Buffett Anoints Successor\nOne of the biggest questions around the future of Berkshire Hathaway in recent years was who would take over the mantle of CEO from Buffett.\nThe Oracle of Omahahas finally gave the answer. He said Greg Abel, who runs the noninsurance businesses, will take over in his stead.\n\"The directors are in agreement that if something were to happen to me tonight, it would be Greg who'd take over tomorrow morning,\" the legendary investor told CNBC.\nBerkshire's Vice Chairman Charlie Munger dropped a massive hint during the company's annual meeting in Los Angeles, mentioning that \"Greg will keep the culture.\"\nAbel, 58, has been a Berkshire vice chairman since 2018, and had long been viewed by analysts as a possible successor. The Canadian is chairman and CEO of Berkshire Hathaway Energy. He has also been vice chairman of Berkshire's noninsurance operations since January 2018.\nBuffett Snaps Up Berkshire Stock\nBerkshire Hathaway revealed in its Q1 earnings report that it had snapped up $6.6 billion more of its shares. It comesafter a record $27.4 billion in repurchaseslast year. This was down from the $9 billion in stock it had purchased in each of the previous two quarters however.\nAfter historically shying away from repurchases, Berkshire Hathaway stock has become one of Buffett's top purchases. Berkshire's aggressive share repurchases contrasts with the M&A deals spun by the investor during and after the 2008 financial crash.\nWhile he has historically been reluctant to splurge on stock repurchases, he explained his change of heart in his latest annual letter to shareholders.\n\"The math of repurchases grinds away slowly, but can be powerful over time,\" he wrote. \"The process offers a simple way for investors to own an ever-expanding portion of exceptional businesses.\"\nBerkshire loosened rules for Buffett to buy back shares in 2018. With Berkshire steadfastly cautious on M&A in recent years, investors have been clamoring for more repurchases.\nBerkshire Hathaway Tweaks Portfolio\nWarren Buffett took a huge stake inVerizon(VZ) stock while dumping JPMorgan (JPM) stock entirely, according to thefirm's latest regulatory filing.\nIts new Verizon stake is massive, with Berkshire paying $8.62 billion for 147 million shares. It now accounts for 3% of the portfolio, making it the No. 6 stock by number of shares held.\nBuffett also opened new stakes inChevron(CVX),Marsh & McLennan(MMC) andEW Scripps(SSP) in Q4.\nBerkshire dumped entirelyPfizer(PFE),JPMorgan Chase(JPM),Barrick Gold(GOLD),M&T Bank(MTB) andPNC Financial(PNC).\nThe conglomerate grew stakes by 117% inT-Mobile(TMUS), 34% inKroger(KR), 28% inMerck(MRK), 20% inAbbVie(ABBV), 11% inBristol-Myers Squibb(BMY), and 1% inRH(RH).\nBuffett cut Berkshire's stake in Apple stock by 6%. It remains the No. 1 stock in his portfolio by market value and No. 2 stock by number of shares held, at 10.6% of the portfolio. He kept an Amazon stake steady.\nDuring its most recent earnings report, the firm revealed it had sold $6.45 billion in stock in Q1 and bought $2.57 billion in stock.\nWarren Buffett Funds Media Deal\nBerkshire Hathaway is a key backer in a deal disclosed Sept. 24 that will see TV station ownerE.W. Scripps(SSP) purchase privately held cable network ION Media for $2.65 billion. The latter firm's flagship, ION Television, is a top 5-ranked U.S. general entertainment network.\nWarren Buffett's firm is snapping up $600 million of Scripps preferred shares to help fund the deal. Scripps stock surged on on the news.\nBerkshire will also receive a warrant that allows it to snap up up to 23.1 million more shares at a price of $13. This adds up to an additional investment of $300 million. Scripps' common shares currently trade at more than 21 each.\nBerkshire Hathaway Coronavirus Exposure\nAs well as its status as an investment vehicle, Berkshire Hathaway is a conglomerate in its own right. It has interests in segments such as railroads, utilities and energy.\nThose sectors, along with other \"real economy\" companies that are Warren Buffett staples, have been hard hit by the coronavirus shutdowns and massive economic contraction. However they should benefit as the economy opens up again.\nBerkshire owns Geico, the No. 2 U.S. auto insurer after State Farm. Currently, states such as California are ordering insurers to give partial credits or refunds of premiums in lines such as private passenger automobile insurance.\nBerkshire also owns BNSF Railway Company, the largest freight railroad network in North America. Rail operators such asUnion Pacific(UNP) andCSX(CSX) have seen business suffer during the pandemic. But rail operators and other transportation companies are seeing business pick up again.\nOther wholly owned businesses such as Dairy Queen and multilevel marketing company Pampered Chef also struggled during coronavirus restrictions, though those are easing.\nWarren Buffett's Big Gas Bill\nWarren Buffett has been criticized for the size of his cash pile. But last July he madehis biggest acquisition in yearswith a $10 billion deal forDominion Energy's (D) assets.\nBerkshire seized the chance to secure Dominion's gas pipeline network after the utility giant andDuke Energy(DUK) unexpectedly aborted plans to build the Atlantic Coast Pipeline.\nBerkshire Hathaway Energy will buy about 7,700 miles of natural gas transmission pipelines and 900 billion cubic feet of gas storage. The all-cash deal includes $4 billion of equity and $5.7 billion of debt. It's set to close in the fourth quarter.\n\"We are very proud to be adding such a great portfolio of natural gas assets to our already strong energy business,\" Buffett said in a statement.\nEnergy has been doing well so far in 2021. For example, the Vanguard Energy ETF (VDE) is up almost 40% since the start of the year.\nBerkshire Hathaway Stock Technical Analysis\nBerkshire Hathaway stock is in a profit-taking zone after breaking out of aflat base, according toMarketSmith analysis. Theideal buy pointwas 235.09. Shares offered a follow-on buy point around 246 in late March after a test of the 10-week line, but are extended from here as well.\nIt could go on to form a new base with an entry point of 295.18, it can continue to consolidate below this level.\nBRKB stock is well clear after pulling away from its50-day moving average, though the key technical benchmark is beginning to catch up. This is a positive sign for holders of the stock.\nTherelative strength lineof Berkshire Hathaway stock has been slippi8ng somewhat of late after a spell of progress that kicked off in mid-March. BRKB stock is outperforming in 2021. So far this year, it is up around 23%, which beats the broader S&P 500's return of almost 13%.\nItsIBD Composite Ratingnow sits at 69 out of 99. This is not ideal, but puts it in the top 31% of stocks tracked overall.\nEarnings are  improving, with EPS accelerating for the past two quarters. However earnings have only grown by an average of 5% over the past three quarters, with coronavirus pandemic lockdowns having an impact. The CAN SLIM systemrecommends investors look for companies with average EPS growth of at least 25% over this time period.\nWall Street is becoming more optimistic for Berkshire Hathaway earnings growth going forward. Analysts are projecting annual earnings will rise 24% 2021, before moderating to 7% growth in 2022.\nWarren Buffett Recommendation\nBerkshire stock had been lagging the S&P 500 index since the end of 2018. Before that, BRKB stock at best moved with the market for a decade. An investor could have bought an index fund or ETF like the SPDR S&P 500 ETF (SPY), and generated similar or higher returns with less stock-specific risk.\n\"In my view, for most people, the best thing to do is owning the S&P 500 index fund, Buffett himself previously said at a Berkshire annual meeting. \"If you bet on America and sustain that position for decades, you'd do far better than buying Treasury securities, or far better than following people. Perhaps with a bias, I don't believe anyone knows what the market is going to do tomorrow, next week, next month, next year.\"\nNevertheless, BRKB stock has been outperforming the S&P 500 so far this year. It could now finally be set for a decent period of outperformance.\nBerkshire Hathaway Earnings Improve\nBerkshire Hathaway earnings per share popped 27% in Q1, rising to $3.05. This was well clear of analyst views for EPS of $2.57. Its operating profit, which excludes some investment results, came in at $7 billion.\nThe conglomerate's total revenue came in at $64.6 billion last quarter, which was also more than analysts expected.\nThe firm's wheeling and dealing on the stock market also saw the firm turn in good gains, increasing approximately $4.69 billion last quarter. However the firm stresses that gains and losses in any particular quarter are \"usually meaningless.\" This fits in with Buffett's longer-term investment philosophy.\nBuffett's Cash Mountain Still Mighty\nBerkshire's cash pile grew to $145.4 billion in Q1 from $138.3 billion in Q4. It is creeping back up to record level it reached in the third quarter of last year. This has raised expectations that Buffett would make a big acquisition, but he has preferred to sit on the sidelines amid spiraling stock prices.\nHaving such a large supply of cash protects the Warren Buffett stock during tough times. It also mean Berkshire Hathaway is able to deploy capital when desirable businesses become available for purchase.\nThe more aggressive buying of Berkshire's own shares of late contrasts with Buffett's deals during and after the Great Recession. This indicates he believes that the latest economic downturn and recovery, so far, offer none of the bargains he has historically pounced on.\nAnalyst Backs Berkshire Stock\nCFRA analyst Catherine Seifert is rating BRKB stock as a hold with a 295 price target. She pointed out the mixed nature of the firm's recent earnings report.\n\"Results reflected a doubling of underwriting profits and 12% higher rail/energy/utility profits, despite 13% lower in investment income,\" she said in a May 3 research note. \"We applaud the 33% rise in energy revenues amid contributions from an acquisition, but rail revenues declined fractionally and insurance premium growth of 4.3% lagged peers.\nNevertheless, she said the shares are currently \"fairly valued versus historical levels.\" The analyst also believes there could be changes afoot once he firm's legendary CEO steps down.\n\"We are disappointed climate change and diversity initiatives failed to be approved at the annual meeting, and think this increases the likelihood of activism in a post-Buffet era,\" she said.\nDifference Between BRKA Stock And BRKB Stock\nThe most obvious difference between Berkshire Hathaway's A class and B class shares is the price. While — at over 200 a share — BRKB stock may be considered relatively expensive, BRKA stock is the most expensive on the market, currently trading near $430,000 a share.\nWarren Buffett decided to introduce the BRKB shares to allow investors to purchase stock directly. Big demand for Berkshire Hathaway stock forced less-moneyed players to plow cash into unit trusts or mutual funds that mirrored his company's holdings.\nBerkshire Hathaway Today\nBerkshire Hathaway operates in four main sectors.\nIts insurance group is one of its biggest cash cows. One of the most famous jewels in the crown is Geico. Other parts of this business include multinational property/casualty and life/health reinsurance company General Re and Berkshire Hathaway Reinsurance Group. The latter underwrites excess-of-loss reinsurance and quota-share coverage globally.\nInsurance operations are a big reason why Berkshire Hathaway earnings can be lumpy.\nIts Regulated Utility Business group includes Berkshire Hathaway Energy, formerly known as MidAmerican Energy. It also includes railway services arm BNSF, North America's largest freight railroad network.\nMeanwhile, the Manufacturing, Service & Retailing group includes Acme Building Brands, Fruit of the Loom and Justin Brands. The likes of Buffalo News, Business Wire, Dairy Queen and NetJets fall under the service subsector. Retailers include See's Candies, Ben Bridge Jeweler, Helzberg Diamond Shops and Star Furniture.\nFinally, the Finance & Financial Products segment includes: Hathaway Credit Corporation, transportation equipment and furniture leasing specialists XTRA and CORT, and BH Finance whose main interest is in proprietary investing strategies.\nIs Berkshire Hathaway Stock A Buy Now?\nWhile Berkshire Hathaway stock has been lagging the S&P 500 index since late 2018, it has been handily outperforming in 2021. However, Berkshire stock is now well clear of its most recent buy zone. Investors keen on the stock could add it to their watchlist, and wait for a new buying opportunity to emerge.\nWhile its Composite Rating is still not up to scratch, it has improved on this front as well. This makes it an option worth watching for investors seeking to add to their portfolio a well established stock with a diversified portfolio of businesses.\nHowever, it is worth remember that, after a late-2018 burst, Berkshire Hathaway earnings growth has been modest and uneven. While Wall Street sees solid EPS growth ahead for Berkshire in 2021 and 2022, it still remains shy of the rates sought by CAN SLIM investors.\nBottom line: Berkshire Hathaway stock is not a buy at the moment. Those interested in buying the ultimate Warren Buffett stock should add it to their watchlist, and wait to see if it forms a new base.","news_type":1,"symbols_score_info":{"BRK.B":0.9,"BRK.A":0.9}},"isVote":1,"tweetType":1,"viewCount":2923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340899729,"gmtCreate":1617367717561,"gmtModify":1704699228238,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Down more","listText":"Down more","text":"Down more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/340899729","repostId":"2124875875","repostType":4,"isVote":1,"tweetType":1,"viewCount":3591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353445116,"gmtCreate":1616517085035,"gmtModify":1704795238950,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here","listText":"Comment here","text":"Comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/353445116","repostId":"1176257801","repostType":4,"repost":{"id":"1176257801","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616512273,"share":"https://ttm.financial/m/news/1176257801?lang=en_US&edition=fundamental","pubTime":"2021-03-23 23:11","market":"us","language":"en","title":"AstraZeneca to publish full trial data after U.S. rebuke","url":"https://stock-news.laohu8.com/highlight/detail?id=1176257801","media":"Reuters","summary":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours a","content":"<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to publish full trial data after U.S. rebuke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to publish full trial data after U.S. rebuke\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-23 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176257801","content_text":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.\nThe rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.\nAstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.\nThe Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.\nIts shares were down 2.5% in London trading.\nThe U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.\nAnthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.\n“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.\n“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”\n‘NEGATIVE REPORTS’\nBesides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.\nThe new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.\n“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.\nRival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.\nThe panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.\nAstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.\nLater analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.\nCONFIDENCE HIT\nConfidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.\nThe European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.\nThe latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.\nAnalysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.\nStephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.\n“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”\nThe AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.\nIt has been granted conditional marketing or emergency use authorization in more than 70 countries.\nMany countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.","news_type":1,"symbols_score_info":{"AZN.UK":0.9,"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353442734,"gmtCreate":1616517049328,"gmtModify":1704795237653,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/353442734","repostId":"1176257801","repostType":4,"repost":{"id":"1176257801","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616512273,"share":"https://ttm.financial/m/news/1176257801?lang=en_US&edition=fundamental","pubTime":"2021-03-23 23:11","market":"us","language":"en","title":"AstraZeneca to publish full trial data after U.S. rebuke","url":"https://stock-news.laohu8.com/highlight/detail?id=1176257801","media":"Reuters","summary":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours a","content":"<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to publish full trial data after U.S. rebuke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to publish full trial data after U.S. rebuke\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-23 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176257801","content_text":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.\nThe rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.\nAstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.\nThe Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.\nIts shares were down 2.5% in London trading.\nThe U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.\nAnthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.\n“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.\n“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”\n‘NEGATIVE REPORTS’\nBesides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.\nThe new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.\n“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.\nRival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.\nThe panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.\nAstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.\nLater analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.\nCONFIDENCE HIT\nConfidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.\nThe European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.\nThe latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.\nAnalysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.\nStephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.\n“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”\nThe AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.\nIt has been granted conditional marketing or emergency use authorization in more than 70 countries.\nMany countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.","news_type":1,"symbols_score_info":{"AZN.UK":0.9,"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3099,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350558835,"gmtCreate":1616237764427,"gmtModify":1704792399058,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Good. Go down more","listText":"Good. Go down more","text":"Good. Go down more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/350558835","repostId":"1147661553","repostType":4,"isVote":1,"tweetType":1,"viewCount":2532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350951931,"gmtCreate":1616153186823,"gmtModify":1704791597317,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Loll","listText":"Loll","text":"Loll","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/350951931","repostId":"1177407243","repostType":4,"repost":{"id":"1177407243","kind":"news","pubTimestamp":1616152583,"share":"https://ttm.financial/m/news/1177407243?lang=en_US&edition=fundamental","pubTime":"2021-03-19 19:16","market":"us","language":"en","title":"Forget AMC Entertainment: These Stocks Will Make You Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=1177407243","media":"Motley Fool","summary":"These innovative companies should run circles around Reddit darling AMC.\n\nOver the past two months, ","content":"<blockquote>\n These innovative companies should run circles around Reddit darling AMC.\n</blockquote>\n<p>Over the past two months, Wall Street has watched a new phenomenon take shape:the Reddit frenzy.</p>\n<p>Retail investors on Reddit's WallStreetBets (WSB) chat room have essentially banded together to buy shares andout-of-the-money call optionson stocks with high levels of short interest. The goal of the WSB community is to create a short squeeze that sends heavily shorted stocks rocketing higher. Since the vast majority of short-sellers are institutional investors and hedge funds, these retail investors view their actions as a way of getting back at the so-called \"big money.\"</p>\n<p>AMC is an extremely popular (and incredibly dangerous) investment</p>\n<p>Although<b>GameStop</b>is the unquestioned king of all Reddit stocks, movie theater chain<b>AMC Entertainment Holdings</b>(NYSE:AMC)easily slots in as the second-most-popular. AMC was one of the market's most short-sold stocks in late January, and its penny-stock share price acted as an insatiable lure for young investors.</p>\n<p>Beyond the Reddit frenzy, optimists are also encouraged by the reopening of the U.S. economy. Movie theaters in New York City and Los Angeles are beginning to reopen, and 21% of the U.S. population has received at least one dose of a coronavirus vaccine. A return to normal appears to be in sight, and investors are betting big on AMC to take advantage of this pent-up demand.</p>\n<p>Unfortunately, the \"buy AMC\" thesisis flawed. The reopening catalyst assumes that there'll be no setbacks in major markets, which is unlikely. It's not yet clear if enough Americans will get the vaccine, which suggests that herd immunity could be pushed further down the road. Coronavirus variants also threaten to diminish the effectiveness of vaccines authorized for emergency use.</p>\n<p>Even more concerning, AMCnarrowly avoided filing for bankruptcy protectionearlier this year. It was forced to sell close to 165 million shares of stock and issued more than $400 million in debt capital to step back from the bankruptcy ledge. If capacity limits don't ease somewhat quickly in key markets, I'm not certain AMC will have enough capital to survive the year -- especially if there are pandemic setbacks.</p>\n<p>But worst of all, AMC's core operating model is now threatened. With consumers stuck in their homes for roughly a year, select streaming services have become competitors.<b>AT&amp;T</b>&nbsp;subsidiary WarnerMedia isreleasing all of its movies in 2021 on HBO Maxthe same day they'll hit theaters.<b>Walt Disney</b>&nbsp;plans to do something similar with a couple of movies on its Disney+ streaming platform.</p>\n<p><b>Forget AMC: These innovative stocks can make you rich</b></p>\n<p>The point being that AMC is a dangerous investment that's liable to lose folks a lot of money. Instead of buying a company that's hanging on by a thread, I'd encourage you to consider purchasing the following three game-changing stocks, all of which have the tools to make you rich.</p>\n<p><b>Ping Identity</b></p>\n<p>Though there are a number of trends that offer double-digit growth potential this decade,cybersecurity might be the safest of the bunch. As more businesses push online and move their data (and that of their customers) onto the cloud, the onus of protecting this data is increasingly going to fall on third-party providers. That's where<b>Ping Identity Holding</b>(NYSE:PING)comes in.</p>\n<p>Whereas most security companies excelled during the pandemic, identity verification specialist Ping Identitystruggled a bit. Full-year sales were essentially flat, with a number of clients opting for one-year subscriptions instead of multiyear plans. But there's plenty of reason to believe that this weakness was pandemic-related and only temporary.</p>\n<p>Even though total sales were flat, the company's focus on subscription services helped boost annual recurring revenue (ARR) by 15% to $259.1 million. Ping also ended the year with 51 customers generating in excess of $1 million in ARR, which is up from 38 clients at the end of 2019. The company is clearly capable of scaling up its services with larger clients, and touts that its services are protecting 60% of Fortune 100 companies.</p>\n<p>What's more, 92% of its fourth-quarter sales were derived from subscriptions, and its subscription gross margin stood at 86% in that quarter of 2020. Even if its ARR growth were to motor along at, say, 15% for the next half-decade, it'd be pretty hard to overlook the cash flow potential when the company's subscriptions are generating 86% gross margin.</p>\n<p>Ping Identity is alsovery reasonably priced. Whereas most cybersecurity stocks are valued at 20 times sales or higher, Ping can be scooped up for around 7 times forecast sales in 2021. It just might be the best value among cybersecurity stocks.</p>\n<p><b>Cresco Labs</b></p>\n<p>Marijuana stocksshould be big-time winners throughout the decade, regardless of what happens with cannabis' classification in Washington. Operating in the most lucrative market in the world, the U.S., multistate operator (MSO)<b>Cresco Labs</b>(OTC:CRLBF)has the potential to make investors rich.</p>\n<p>As with most MSOs, Cresco's success will depend somewhat on its retail presence. The company entered the year with only 20 open dispensaries, but has been leaning on acquisitions to expand. Closing the Verdant Creations deal maximized its presence in Ohio, while the pending<b>Bluma Wellness</b>buyout will give the company a healthy presence in medical-marijuana-legal Florida.</p>\n<p>Yet what's interesting about Cresco Labs is that its retail game planmostly revolves around limited-license states. In particular, over 60% of its open locations are in states where the number of retail licenses is capped by regulators. Pushing into states with caps on dispensary licenses is a smart way for Cresco to build up its brand while facing minimal competition.</p>\n<p>However, thebigger growth driver for the companyis likely to be its wholesale operations. Even though wholesale cannabis offers lower margins than retail, Cresco has more than enough volume to overlook any margin differences. That's because it holds one of the highly coveted cannabis distribution licenses in California, which allows the company to place proprietary and third-party products into more than 575 dispensaries throughout the Golden State.</p>\n<p>With Cresco's projected growth surpassing many of its peers, it has a good chance to put some serious green into the pockets of its shareholders.</p>\n<p><b>Intuitive Surgical</b></p>\n<p>Lastly, investors should forget all about AMC Entertainment andbuy into a real game-changerin the healthcare sector,<b>Intuitive Surgical</b>(NASDAQ:ISRG).</p>\n<p>Intuitive Surgical is best known for its robotic-assisted surgical system, the da Vinci, which allows surgeons to make precise incisions that can reduce scarring and shorten hospital stays. For insurers, it can lead to higher up-front costs, but reduce extended hospital stays that can prove even costlier.</p>\n<p>The da Vinci system is the unquestioned leader in robotic-assisted surgery. Intuitive has placed close to 6,000 of its machines worldwide since 2000, which is more than all of the company's competitors combined. The company has been able to build priceless rapport with surgeons in hospitals and surgical centers, which makes ithighly unlikelythat we'll see its clients switch to a competing system.</p>\n<p>But it's not just the company's overwhelming competitive edge that makes it such an attractive stock. Its operating model isdesigned to grow more efficient over time. As more da Vinci systems are installed, a higher percentage of sales will be derived from segments with juicier margins, such as instruments and accessories sold with each procedure, as well as system servicing.</p>\n<p>Intuitive Surgical is just beginning to realize its opportunity with its innovative soft-tissue surgical solutions. Expect the da Vinci to pick up significant market share in thoracic, colorectal, and general soft-tissue procedures throughout the decade.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forget AMC Entertainment: These Stocks Will Make You Rich</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForget AMC Entertainment: These Stocks Will Make You Rich\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-19 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/19/forget-amc-entertainment-these-stock-make-you-rich/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These innovative companies should run circles around Reddit darling AMC.\n\nOver the past two months, Wall Street has watched a new phenomenon take shape:the Reddit frenzy.\nRetail investors on Reddit's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/19/forget-amc-entertainment-these-stock-make-you-rich/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRLBF":"Cresco Labs Inc.","PING":"Ping Identity Holding","ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/03/19/forget-amc-entertainment-these-stock-make-you-rich/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177407243","content_text":"These innovative companies should run circles around Reddit darling AMC.\n\nOver the past two months, Wall Street has watched a new phenomenon take shape:the Reddit frenzy.\nRetail investors on Reddit's WallStreetBets (WSB) chat room have essentially banded together to buy shares andout-of-the-money call optionson stocks with high levels of short interest. The goal of the WSB community is to create a short squeeze that sends heavily shorted stocks rocketing higher. Since the vast majority of short-sellers are institutional investors and hedge funds, these retail investors view their actions as a way of getting back at the so-called \"big money.\"\nAMC is an extremely popular (and incredibly dangerous) investment\nAlthoughGameStopis the unquestioned king of all Reddit stocks, movie theater chainAMC Entertainment Holdings(NYSE:AMC)easily slots in as the second-most-popular. AMC was one of the market's most short-sold stocks in late January, and its penny-stock share price acted as an insatiable lure for young investors.\nBeyond the Reddit frenzy, optimists are also encouraged by the reopening of the U.S. economy. Movie theaters in New York City and Los Angeles are beginning to reopen, and 21% of the U.S. population has received at least one dose of a coronavirus vaccine. A return to normal appears to be in sight, and investors are betting big on AMC to take advantage of this pent-up demand.\nUnfortunately, the \"buy AMC\" thesisis flawed. The reopening catalyst assumes that there'll be no setbacks in major markets, which is unlikely. It's not yet clear if enough Americans will get the vaccine, which suggests that herd immunity could be pushed further down the road. Coronavirus variants also threaten to diminish the effectiveness of vaccines authorized for emergency use.\nEven more concerning, AMCnarrowly avoided filing for bankruptcy protectionearlier this year. It was forced to sell close to 165 million shares of stock and issued more than $400 million in debt capital to step back from the bankruptcy ledge. If capacity limits don't ease somewhat quickly in key markets, I'm not certain AMC will have enough capital to survive the year -- especially if there are pandemic setbacks.\nBut worst of all, AMC's core operating model is now threatened. With consumers stuck in their homes for roughly a year, select streaming services have become competitors.AT&T subsidiary WarnerMedia isreleasing all of its movies in 2021 on HBO Maxthe same day they'll hit theaters.Walt Disney plans to do something similar with a couple of movies on its Disney+ streaming platform.\nForget AMC: These innovative stocks can make you rich\nThe point being that AMC is a dangerous investment that's liable to lose folks a lot of money. Instead of buying a company that's hanging on by a thread, I'd encourage you to consider purchasing the following three game-changing stocks, all of which have the tools to make you rich.\nPing Identity\nThough there are a number of trends that offer double-digit growth potential this decade,cybersecurity might be the safest of the bunch. As more businesses push online and move their data (and that of their customers) onto the cloud, the onus of protecting this data is increasingly going to fall on third-party providers. That's wherePing Identity Holding(NYSE:PING)comes in.\nWhereas most security companies excelled during the pandemic, identity verification specialist Ping Identitystruggled a bit. Full-year sales were essentially flat, with a number of clients opting for one-year subscriptions instead of multiyear plans. But there's plenty of reason to believe that this weakness was pandemic-related and only temporary.\nEven though total sales were flat, the company's focus on subscription services helped boost annual recurring revenue (ARR) by 15% to $259.1 million. Ping also ended the year with 51 customers generating in excess of $1 million in ARR, which is up from 38 clients at the end of 2019. The company is clearly capable of scaling up its services with larger clients, and touts that its services are protecting 60% of Fortune 100 companies.\nWhat's more, 92% of its fourth-quarter sales were derived from subscriptions, and its subscription gross margin stood at 86% in that quarter of 2020. Even if its ARR growth were to motor along at, say, 15% for the next half-decade, it'd be pretty hard to overlook the cash flow potential when the company's subscriptions are generating 86% gross margin.\nPing Identity is alsovery reasonably priced. Whereas most cybersecurity stocks are valued at 20 times sales or higher, Ping can be scooped up for around 7 times forecast sales in 2021. It just might be the best value among cybersecurity stocks.\nCresco Labs\nMarijuana stocksshould be big-time winners throughout the decade, regardless of what happens with cannabis' classification in Washington. Operating in the most lucrative market in the world, the U.S., multistate operator (MSO)Cresco Labs(OTC:CRLBF)has the potential to make investors rich.\nAs with most MSOs, Cresco's success will depend somewhat on its retail presence. The company entered the year with only 20 open dispensaries, but has been leaning on acquisitions to expand. Closing the Verdant Creations deal maximized its presence in Ohio, while the pendingBluma Wellnessbuyout will give the company a healthy presence in medical-marijuana-legal Florida.\nYet what's interesting about Cresco Labs is that its retail game planmostly revolves around limited-license states. In particular, over 60% of its open locations are in states where the number of retail licenses is capped by regulators. Pushing into states with caps on dispensary licenses is a smart way for Cresco to build up its brand while facing minimal competition.\nHowever, thebigger growth driver for the companyis likely to be its wholesale operations. Even though wholesale cannabis offers lower margins than retail, Cresco has more than enough volume to overlook any margin differences. That's because it holds one of the highly coveted cannabis distribution licenses in California, which allows the company to place proprietary and third-party products into more than 575 dispensaries throughout the Golden State.\nWith Cresco's projected growth surpassing many of its peers, it has a good chance to put some serious green into the pockets of its shareholders.\nIntuitive Surgical\nLastly, investors should forget all about AMC Entertainment andbuy into a real game-changerin the healthcare sector,Intuitive Surgical(NASDAQ:ISRG).\nIntuitive Surgical is best known for its robotic-assisted surgical system, the da Vinci, which allows surgeons to make precise incisions that can reduce scarring and shorten hospital stays. For insurers, it can lead to higher up-front costs, but reduce extended hospital stays that can prove even costlier.\nThe da Vinci system is the unquestioned leader in robotic-assisted surgery. Intuitive has placed close to 6,000 of its machines worldwide since 2000, which is more than all of the company's competitors combined. The company has been able to build priceless rapport with surgeons in hospitals and surgical centers, which makes ithighly unlikelythat we'll see its clients switch to a competing system.\nBut it's not just the company's overwhelming competitive edge that makes it such an attractive stock. Its operating model isdesigned to grow more efficient over time. As more da Vinci systems are installed, a higher percentage of sales will be derived from segments with juicier margins, such as instruments and accessories sold with each procedure, as well as system servicing.\nIntuitive Surgical is just beginning to realize its opportunity with its innovative soft-tissue surgical solutions. Expect the da Vinci to pick up significant market share in thoracic, colorectal, and general soft-tissue procedures throughout the decade.","news_type":1,"symbols_score_info":{"ISRG":0.9,"PING":0.9,"CRLBF":0.9}},"isVote":1,"tweetType":1,"viewCount":2549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327340384,"gmtCreate":1616063567048,"gmtModify":1704790399263,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Like n comment if u want Nio go to $65","listText":"Like n comment if u want Nio go to $65","text":"Like n comment if u want Nio go to $65","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327340384","repostId":"1176074161","repostType":4,"isVote":1,"tweetType":1,"viewCount":819,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324291591,"gmtCreate":1615992921113,"gmtModify":1704789505358,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here. It will fly","listText":"Comment here. It will fly","text":"Comment here. It will fly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324291591","repostId":"1167332168","repostType":4,"isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325185354,"gmtCreate":1615876186878,"gmtModify":1704787792149,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here","listText":"Comment here","text":"Comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/325185354","repostId":"1117628563","repostType":4,"repost":{"id":"1117628563","kind":"news","pubTimestamp":1615875641,"share":"https://ttm.financial/m/news/1117628563?lang=en_US&edition=fundamental","pubTime":"2021-03-16 14:20","market":"us","language":"en","title":"Netflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1117628563","media":"Barrons","summary":"Netflix stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potenti","content":"<p>Netflix&nbsp;stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potential plans to crack down on password sharing.</p>\n<p>Benchmark analyst Matthew Harrigan, who rates the stock a Sell, lowered his price target to $472 from $485. Harriganrefers to reportsthat certain users received messages Friday asking them to make their own account if they don’t live with the actual subscriber.</p>\n<p>“This test is designed to help ensure that people using Netflix accounts are authorized to do so,” a spokesperson&nbsp;told MarketWatch.</p>\n<p>Harrigan argues any such crackdown will require finesse. He refers to estimates from research firm Magid that about 33% of Netflix members share passwords but argues that those benefiting from password sharing may be more casual or economically sensitive users.</p>\n<p>“Although a crackdown on password sharing could emerge as an at least marginal long-term positive, we believe that it somewhat dampens pricing power even as competition from Disney+ and others mounts,” he writes.</p>\n<p>Harrigan added that Netflix stock’s appealhas been diminished&nbsp;by rising competition from Disney+ and the rollout of Covid-19 vaccinations. He estimates Netflix will hit 313 million global members in 2024, not far ahead of&nbsp;Walt Disney’s(DIS) global target of&nbsp;230 million to 260 million Disney+ subscribers&nbsp;during fiscal 2024.</p>\n<p>“Disney will almost certainly emerge as the overall global streaming leader if ESPN+ and Hulu are aggregated as well,” he writes. “Disney+ achieved 100M global customers on its platforms earlier this month only 16 months after launch—which had taken Netflix a decade to achieve.”</p>\n<p>On the side of the debate is BMO Capital Markets analyst Daniel Salmon, who has an Outperform rating and a $700 price target. He titled his late-Sunday night note, “The Password Is: StillTopPick42021.”</p>\n<p>He argues that Netflix has always had the option to clamp down on password sharing in its back pocket, and believes such a move can drive gross subscriber additions and help member growth as the company approaches tough year-over-year comparisons from the 2020 shutdowns. The move could drive upside to consensus expectations for subscribers during the fiscal first quarter, according to Salmon.</p>\n<p>Netflix stock rose 0.4% to $520.25 on Monday, while the&nbsp;S&amp;P 500 index&nbsp;was up about 0.7%. There are 40 analysts covering the stock listed by FactSet. Of that group, 27 analysts have Buy or equivalent ratings, while four have Sell or equivalent ratings. The rest are in between. But the mean price target for the stock is $626.88, according to FactSet, which implies about 20% upside from recent levels.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 14:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/netflix-may-crack-down-on-password-sharing-what-it-means-for-the-stock-51615849524?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Netflix stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potential plans to crack down on password sharing.\nBenchmark analyst Matthew Harrigan, who rates the stock ...</p>\n\n<a href=\"https://www.barrons.com/articles/netflix-may-crack-down-on-password-sharing-what-it-means-for-the-stock-51615849524?mod=RTA\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://www.barrons.com/articles/netflix-may-crack-down-on-password-sharing-what-it-means-for-the-stock-51615849524?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117628563","content_text":"Netflix stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potential plans to crack down on password sharing.\nBenchmark analyst Matthew Harrigan, who rates the stock a Sell, lowered his price target to $472 from $485. Harriganrefers to reportsthat certain users received messages Friday asking them to make their own account if they don’t live with the actual subscriber.\n“This test is designed to help ensure that people using Netflix accounts are authorized to do so,” a spokesperson told MarketWatch.\nHarrigan argues any such crackdown will require finesse. He refers to estimates from research firm Magid that about 33% of Netflix members share passwords but argues that those benefiting from password sharing may be more casual or economically sensitive users.\n“Although a crackdown on password sharing could emerge as an at least marginal long-term positive, we believe that it somewhat dampens pricing power even as competition from Disney+ and others mounts,” he writes.\nHarrigan added that Netflix stock’s appealhas been diminished by rising competition from Disney+ and the rollout of Covid-19 vaccinations. He estimates Netflix will hit 313 million global members in 2024, not far ahead of Walt Disney’s(DIS) global target of 230 million to 260 million Disney+ subscribers during fiscal 2024.\n“Disney will almost certainly emerge as the overall global streaming leader if ESPN+ and Hulu are aggregated as well,” he writes. “Disney+ achieved 100M global customers on its platforms earlier this month only 16 months after launch—which had taken Netflix a decade to achieve.”\nOn the side of the debate is BMO Capital Markets analyst Daniel Salmon, who has an Outperform rating and a $700 price target. He titled his late-Sunday night note, “The Password Is: StillTopPick42021.”\nHe argues that Netflix has always had the option to clamp down on password sharing in its back pocket, and believes such a move can drive gross subscriber additions and help member growth as the company approaches tough year-over-year comparisons from the 2020 shutdowns. The move could drive upside to consensus expectations for subscribers during the fiscal first quarter, according to Salmon.\nNetflix stock rose 0.4% to $520.25 on Monday, while the S&P 500 index was up about 0.7%. There are 40 analysts covering the stock listed by FactSet. Of that group, 27 analysts have Buy or equivalent ratings, while four have Sell or equivalent ratings. The rest are in between. But the mean price target for the stock is $626.88, according to FactSet, which implies about 20% upside from recent levels.","news_type":1,"symbols_score_info":{"NFLX":0.9}},"isVote":1,"tweetType":1,"viewCount":969,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322400880,"gmtCreate":1615818691740,"gmtModify":1704787059407,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment me","listText":"Comment me","text":"Comment me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322400880","repostId":"1168136589","repostType":4,"repost":{"id":"1168136589","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1615817089,"share":"https://ttm.financial/m/news/1168136589?lang=en_US&edition=fundamental","pubTime":"2021-03-15 22:04","market":"us","language":"en","title":"AMC jumps about 18% as it plans to open all California locations","url":"https://stock-news.laohu8.com/highlight/detail?id=1168136589","media":"Tiger Newspress","summary":"AMC Entertainment is17.83% higheron its plans toreopen nearly all of its California locations this w","content":"<p>AMC Entertainment&nbsp;is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.</p><p><img src=\"https://static.tigerbbs.com/0c13207d6d736ff15684ecc67214e7b0\" tg-width=\"724\" tg-height=\"495\"></p><p>AMC's Burbank 16 and Century City 15 will reopen this afternoon.</p><p>Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.</p><p>\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.</p><p>Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.</p><p>As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.</p><p>AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC jumps about 18% as it plans to open all California locations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC jumps about 18% as it plans to open all California locations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-15 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC Entertainment&nbsp;is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.</p><p><img src=\"https://static.tigerbbs.com/0c13207d6d736ff15684ecc67214e7b0\" tg-width=\"724\" tg-height=\"495\"></p><p>AMC's Burbank 16 and Century City 15 will reopen this afternoon.</p><p>Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.</p><p>\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.</p><p>Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.</p><p>As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.</p><p>AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168136589","content_text":"AMC Entertainment is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.AMC's Burbank 16 and Century City 15 will reopen this afternoon.Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322577128,"gmtCreate":1615818664964,"gmtModify":1704787057635,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322577128","repostId":"1168136589","repostType":4,"repost":{"id":"1168136589","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1615817089,"share":"https://ttm.financial/m/news/1168136589?lang=en_US&edition=fundamental","pubTime":"2021-03-15 22:04","market":"us","language":"en","title":"AMC jumps about 18% as it plans to open all California locations","url":"https://stock-news.laohu8.com/highlight/detail?id=1168136589","media":"Tiger Newspress","summary":"AMC Entertainment is17.83% higheron its plans toreopen nearly all of its California locations this w","content":"<p>AMC Entertainment&nbsp;is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.</p><p><img src=\"https://static.tigerbbs.com/0c13207d6d736ff15684ecc67214e7b0\" tg-width=\"724\" tg-height=\"495\"></p><p>AMC's Burbank 16 and Century City 15 will reopen this afternoon.</p><p>Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.</p><p>\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.</p><p>Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.</p><p>As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.</p><p>AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC jumps about 18% as it plans to open all California locations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC jumps about 18% as it plans to open all California locations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-15 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC Entertainment&nbsp;is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.</p><p><img src=\"https://static.tigerbbs.com/0c13207d6d736ff15684ecc67214e7b0\" tg-width=\"724\" tg-height=\"495\"></p><p>AMC's Burbank 16 and Century City 15 will reopen this afternoon.</p><p>Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.</p><p>\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.</p><p>Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.</p><p>As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.</p><p>AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168136589","content_text":"AMC Entertainment is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.AMC's Burbank 16 and Century City 15 will reopen this afternoon.Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1075,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328699882,"gmtCreate":1615517278646,"gmtModify":1704783973420,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328699882","repostId":"1134483939","repostType":4,"isVote":1,"tweetType":1,"viewCount":827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321797500,"gmtCreate":1615468933700,"gmtModify":1704783168051,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here","listText":"Comment here","text":"Comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/321797500","repostId":"1185608276","repostType":4,"repost":{"id":"1185608276","kind":"news","pubTimestamp":1615463354,"share":"https://ttm.financial/m/news/1185608276?lang=en_US&edition=fundamental","pubTime":"2021-03-11 19:49","market":"us","language":"en","title":"Cathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1185608276","media":"The Wall Street Journal","summary":"Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead\nMore t","content":"<p>Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead</p>\n<p>More than half the companies in Cathie Wood’s five popular exchange-traded funds at ARK Investment Management LLC were unprofitable in their latest year, a characteristic that analysts say will likely add to the volatility in these funds in the coming months.</p>\n<p>Of the 165 stocks included in ARK’s actively managed ETFs, 85 generated net losses in their latest fiscal years, according to an analysis by Dow Jones Market Data. That made the funds&nbsp;particularly vulnerable to dramatic swings&nbsp;when investors turned their backs on growth stocks in favor of shares that shine when the economy prospers.</p>\n<p>Despite&nbsp;this week’s rebound in tech stocks, all five of ARK’s ETFs remain down at least 18% from their mid-February highs, trailing the Nasdaq Composite, which is off 7.3% from its Feb. 12 record.</p>\n<p>The pain has been most acute among shares of the unprofitable companies in ARK’s funds. Those stocks have fallen on average 23% over the past month, according to a DJMD analysis of ARK’s holdings and FactSet data, while the profitable holdings are down 10% over the same period.</p>\n<p>“These stocks are inherently more risky than the broader market,” said Ben Johnson, director of global ETF research at Morningstar.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-11 19:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/cathie-woods-ark-finds-gains-and-pain-in-money-losing-companies-11615458601?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead\nMore than half the companies in Cathie Wood’s five popular exchange-traded funds at ARK Investment ...</p>\n\n<a href=\"https://www.wsj.com/articles/cathie-woods-ark-finds-gains-and-pain-in-money-losing-companies-11615458601?mod=hp_lead_pos3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKF":"ARK Fintech Innovation ETF","ARKK":"ARK Innovation ETF"},"source_url":"https://www.wsj.com/articles/cathie-woods-ark-finds-gains-and-pain-in-money-losing-companies-11615458601?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185608276","content_text":"Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead\nMore than half the companies in Cathie Wood’s five popular exchange-traded funds at ARK Investment Management LLC were unprofitable in their latest year, a characteristic that analysts say will likely add to the volatility in these funds in the coming months.\nOf the 165 stocks included in ARK’s actively managed ETFs, 85 generated net losses in their latest fiscal years, according to an analysis by Dow Jones Market Data. That made the funds particularly vulnerable to dramatic swings when investors turned their backs on growth stocks in favor of shares that shine when the economy prospers.\nDespite this week’s rebound in tech stocks, all five of ARK’s ETFs remain down at least 18% from their mid-February highs, trailing the Nasdaq Composite, which is off 7.3% from its Feb. 12 record.\nThe pain has been most acute among shares of the unprofitable companies in ARK’s funds. Those stocks have fallen on average 23% over the past month, according to a DJMD analysis of ARK’s holdings and FactSet data, while the profitable holdings are down 10% over the same period.\n“These stocks are inherently more risky than the broader market,” said Ben Johnson, director of global ETF research at Morningstar.","news_type":1,"symbols_score_info":{"ARKK":0.9,"ARKF":0.9}},"isVote":1,"tweetType":1,"viewCount":1218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321794380,"gmtCreate":1615468847140,"gmtModify":1704783165950,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/321794380","repostId":"1115960803","repostType":4,"isVote":1,"tweetType":1,"viewCount":963,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323299614,"gmtCreate":1615342393938,"gmtModify":1704781403557,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323299614","repostId":"1102807948","repostType":4,"isVote":1,"tweetType":1,"viewCount":1019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362435551,"gmtCreate":1614656277573,"gmtModify":1704773612403,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Good move","listText":"Good move","text":"Good move","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362435551","repostId":"2116856399","repostType":4,"repost":{"id":"2116856399","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1614648660,"share":"https://ttm.financial/m/news/2116856399?lang=en_US&edition=fundamental","pubTime":"2021-03-02 09:31","market":"us","language":"en","title":"All Apple retail stores in U.S. open for first time in almost a year; stock jumps","url":"https://stock-news.laohu8.com/highlight/detail?id=2116856399","media":"Dow Jones","summary":"For the first time in almost a year, all of Apple Inc.'s U.S. retail stores are open.That milestone, along with news over the weekend  jumping more than 5% on Monday, their biggest gain in more than four months.Apple closed all its stores outside China on March 13, 2020 , as the COVID-19 pandemic swept the globe. Its stores in China had closed that February.But as of Monday, all 270 Apple stores  in the U.S. were open in some capacity, though some still have restrictions, such as being appointme","content":"<p>For the first time in almost a year, all of Apple Inc.'s U.S. retail stores are open.</p><p>That milestone, along with news over the weekend  jumping more than 5% on Monday, their biggest gain in more than four months.</p><p>Apple closed all its stores outside China on March 13, 2020 , as the COVID-19 pandemic swept the globe. Its stores in China had closed that February.</p><p>But as of Monday, all 270 Apple stores  in the U.S. were open in some capacity, though some still have restrictions, such as being appointment-only. Stores in Texas were the last to reopen Monday, following additional delays caused by February's crippling winter storm.</p><p>9to5 Mac  was the first to report the openings. It also said the only Apple stores remaining closed worldwide are about a dozen in France and Brazil.</p><p>A number of U.S. stores had reopened starting last May , but many were forced to close again as the pandemic worsened and local restrictions were tightened. The reopened stores are seen as somewhat of a bellwether on local business conditions, and are an encouraging sign of an economic recovery as COVID-19 vaccines get distributed more widely and cases fall nationwide.</p><p>Apple shares rose more than 5% on Monday, their best showing since a 6.4% gain on Oct. 12. Apple stock is down 3.7% year to date, but is up 71% over the past 12 months, compared to Dow Jones Industrial Average  gains of 3% this year and 18% over the past year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>All Apple retail stores in U.S. open for first time in almost a year; stock jumps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAll Apple retail stores in U.S. open for first time in almost a year; stock jumps\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-03-02 09:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>For the first time in almost a year, all of Apple Inc.'s U.S. retail stores are open.</p><p>That milestone, along with news over the weekend  jumping more than 5% on Monday, their biggest gain in more than four months.</p><p>Apple closed all its stores outside China on March 13, 2020 , as the COVID-19 pandemic swept the globe. Its stores in China had closed that February.</p><p>But as of Monday, all 270 Apple stores  in the U.S. were open in some capacity, though some still have restrictions, such as being appointment-only. Stores in Texas were the last to reopen Monday, following additional delays caused by February's crippling winter storm.</p><p>9to5 Mac  was the first to report the openings. It also said the only Apple stores remaining closed worldwide are about a dozen in France and Brazil.</p><p>A number of U.S. stores had reopened starting last May , but many were forced to close again as the pandemic worsened and local restrictions were tightened. The reopened stores are seen as somewhat of a bellwether on local business conditions, and are an encouraging sign of an economic recovery as COVID-19 vaccines get distributed more widely and cases fall nationwide.</p><p>Apple shares rose more than 5% on Monday, their best showing since a 6.4% gain on Oct. 12. Apple stock is down 3.7% year to date, but is up 71% over the past 12 months, compared to Dow Jones Industrial Average  gains of 3% this year and 18% over the past year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","03086":"华夏纳指","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2116856399","content_text":"For the first time in almost a year, all of Apple Inc.'s U.S. retail stores are open.That milestone, along with news over the weekend  jumping more than 5% on Monday, their biggest gain in more than four months.Apple closed all its stores outside China on March 13, 2020 , as the COVID-19 pandemic swept the globe. Its stores in China had closed that February.But as of Monday, all 270 Apple stores  in the U.S. were open in some capacity, though some still have restrictions, such as being appointment-only. Stores in Texas were the last to reopen Monday, following additional delays caused by February's crippling winter storm.9to5 Mac  was the first to report the openings. It also said the only Apple stores remaining closed worldwide are about a dozen in France and Brazil.A number of U.S. stores had reopened starting last May , but many were forced to close again as the pandemic worsened and local restrictions were tightened. The reopened stores are seen as somewhat of a bellwether on local business conditions, and are an encouraging sign of an economic recovery as COVID-19 vaccines get distributed more widely and cases fall nationwide.Apple shares rose more than 5% on Monday, their best showing since a 6.4% gain on Oct. 12. Apple stock is down 3.7% year to date, but is up 71% over the past 12 months, compared to Dow Jones Industrial Average  gains of 3% this year and 18% over the past year.","news_type":1,"symbols_score_info":{"AAPL":0.9,"09086":0.9,"03086":0.9}},"isVote":1,"tweetType":1,"viewCount":746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":322400880,"gmtCreate":1615818691740,"gmtModify":1704787059407,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment me","listText":"Comment me","text":"Comment me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322400880","repostId":"1168136589","repostType":4,"repost":{"id":"1168136589","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1615817089,"share":"https://ttm.financial/m/news/1168136589?lang=en_US&edition=fundamental","pubTime":"2021-03-15 22:04","market":"us","language":"en","title":"AMC jumps about 18% as it plans to open all California locations","url":"https://stock-news.laohu8.com/highlight/detail?id=1168136589","media":"Tiger Newspress","summary":"AMC Entertainment is17.83% higheron its plans toreopen nearly all of its California locations this w","content":"<p>AMC Entertainment&nbsp;is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.</p><p><img src=\"https://static.tigerbbs.com/0c13207d6d736ff15684ecc67214e7b0\" tg-width=\"724\" tg-height=\"495\"></p><p>AMC's Burbank 16 and Century City 15 will reopen this afternoon.</p><p>Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.</p><p>\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.</p><p>Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.</p><p>As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.</p><p>AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC jumps about 18% as it plans to open all California locations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC jumps about 18% as it plans to open all California locations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-15 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC Entertainment&nbsp;is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.</p><p><img src=\"https://static.tigerbbs.com/0c13207d6d736ff15684ecc67214e7b0\" tg-width=\"724\" tg-height=\"495\"></p><p>AMC's Burbank 16 and Century City 15 will reopen this afternoon.</p><p>Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.</p><p>\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.</p><p>Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.</p><p>As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.</p><p>AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168136589","content_text":"AMC Entertainment is17.83% higheron its plans toreopen nearly all of its California locations this week, startingwith two flagship locations in Los Angeles today.AMC's Burbank 16 and Century City 15 will reopen this afternoon.Meanwhile, the remaining 23 movie theaters in Los Angeles County will be back in action on Friday, March 19. And the company plans to open nearly all 56 California locations Friday so long as local approvals are in place.\"To put the magnitude of Los Angeles reopening in perspective, as a movie market, the L.A. DMA is about double the size of the New York City market, which just finished last weekend as the No. 1 DMA in our circuit for box office,\" says AMC CEO Adam Aron.Meanwhile, AMC's various rallies and equity raises have resulted in China's Dalian Wanda Group losing majority control, though it continues to be its largest shareholder.As of October, Wanda held 37.7% of AMC and 64.5% of its voting power, but AMC notes Wanda has now shrunk its stake and voting power to 9.8%.AMC also indicated in its earnings this week that it had come to an acceptable deal with Warner Bros. in order tokeep exhibiting those films even as they appear simultaneously on HBO Max.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325185354,"gmtCreate":1615876186878,"gmtModify":1704787792149,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here","listText":"Comment here","text":"Comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/325185354","repostId":"1117628563","repostType":4,"repost":{"id":"1117628563","kind":"news","pubTimestamp":1615875641,"share":"https://ttm.financial/m/news/1117628563?lang=en_US&edition=fundamental","pubTime":"2021-03-16 14:20","market":"us","language":"en","title":"Netflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1117628563","media":"Barrons","summary":"Netflix stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potenti","content":"<p>Netflix&nbsp;stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potential plans to crack down on password sharing.</p>\n<p>Benchmark analyst Matthew Harrigan, who rates the stock a Sell, lowered his price target to $472 from $485. Harriganrefers to reportsthat certain users received messages Friday asking them to make their own account if they don’t live with the actual subscriber.</p>\n<p>“This test is designed to help ensure that people using Netflix accounts are authorized to do so,” a spokesperson&nbsp;told MarketWatch.</p>\n<p>Harrigan argues any such crackdown will require finesse. He refers to estimates from research firm Magid that about 33% of Netflix members share passwords but argues that those benefiting from password sharing may be more casual or economically sensitive users.</p>\n<p>“Although a crackdown on password sharing could emerge as an at least marginal long-term positive, we believe that it somewhat dampens pricing power even as competition from Disney+ and others mounts,” he writes.</p>\n<p>Harrigan added that Netflix stock’s appealhas been diminished&nbsp;by rising competition from Disney+ and the rollout of Covid-19 vaccinations. He estimates Netflix will hit 313 million global members in 2024, not far ahead of&nbsp;Walt Disney’s(DIS) global target of&nbsp;230 million to 260 million Disney+ subscribers&nbsp;during fiscal 2024.</p>\n<p>“Disney will almost certainly emerge as the overall global streaming leader if ESPN+ and Hulu are aggregated as well,” he writes. “Disney+ achieved 100M global customers on its platforms earlier this month only 16 months after launch—which had taken Netflix a decade to achieve.”</p>\n<p>On the side of the debate is BMO Capital Markets analyst Daniel Salmon, who has an Outperform rating and a $700 price target. He titled his late-Sunday night note, “The Password Is: StillTopPick42021.”</p>\n<p>He argues that Netflix has always had the option to clamp down on password sharing in its back pocket, and believes such a move can drive gross subscriber additions and help member growth as the company approaches tough year-over-year comparisons from the 2020 shutdowns. The move could drive upside to consensus expectations for subscribers during the fiscal first quarter, according to Salmon.</p>\n<p>Netflix stock rose 0.4% to $520.25 on Monday, while the&nbsp;S&amp;P 500 index&nbsp;was up about 0.7%. There are 40 analysts covering the stock listed by FactSet. Of that group, 27 analysts have Buy or equivalent ratings, while four have Sell or equivalent ratings. The rest are in between. But the mean price target for the stock is $626.88, according to FactSet, which implies about 20% upside from recent levels.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix May Crack Down on Password Sharing. Here’s What It Means for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 14:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/netflix-may-crack-down-on-password-sharing-what-it-means-for-the-stock-51615849524?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Netflix stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potential plans to crack down on password sharing.\nBenchmark analyst Matthew Harrigan, who rates the stock ...</p>\n\n<a href=\"https://www.barrons.com/articles/netflix-may-crack-down-on-password-sharing-what-it-means-for-the-stock-51615849524?mod=RTA\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://www.barrons.com/articles/netflix-may-crack-down-on-password-sharing-what-it-means-for-the-stock-51615849524?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117628563","content_text":"Netflix stock rose on Monday as analysts on both sides of the Bull-Bear debate weighed in on potential plans to crack down on password sharing.\nBenchmark analyst Matthew Harrigan, who rates the stock a Sell, lowered his price target to $472 from $485. Harriganrefers to reportsthat certain users received messages Friday asking them to make their own account if they don’t live with the actual subscriber.\n“This test is designed to help ensure that people using Netflix accounts are authorized to do so,” a spokesperson told MarketWatch.\nHarrigan argues any such crackdown will require finesse. He refers to estimates from research firm Magid that about 33% of Netflix members share passwords but argues that those benefiting from password sharing may be more casual or economically sensitive users.\n“Although a crackdown on password sharing could emerge as an at least marginal long-term positive, we believe that it somewhat dampens pricing power even as competition from Disney+ and others mounts,” he writes.\nHarrigan added that Netflix stock’s appealhas been diminished by rising competition from Disney+ and the rollout of Covid-19 vaccinations. He estimates Netflix will hit 313 million global members in 2024, not far ahead of Walt Disney’s(DIS) global target of 230 million to 260 million Disney+ subscribers during fiscal 2024.\n“Disney will almost certainly emerge as the overall global streaming leader if ESPN+ and Hulu are aggregated as well,” he writes. “Disney+ achieved 100M global customers on its platforms earlier this month only 16 months after launch—which had taken Netflix a decade to achieve.”\nOn the side of the debate is BMO Capital Markets analyst Daniel Salmon, who has an Outperform rating and a $700 price target. He titled his late-Sunday night note, “The Password Is: StillTopPick42021.”\nHe argues that Netflix has always had the option to clamp down on password sharing in its back pocket, and believes such a move can drive gross subscriber additions and help member growth as the company approaches tough year-over-year comparisons from the 2020 shutdowns. The move could drive upside to consensus expectations for subscribers during the fiscal first quarter, according to Salmon.\nNetflix stock rose 0.4% to $520.25 on Monday, while the S&P 500 index was up about 0.7%. There are 40 analysts covering the stock listed by FactSet. Of that group, 27 analysts have Buy or equivalent ratings, while four have Sell or equivalent ratings. The rest are in between. But the mean price target for the stock is $626.88, according to FactSet, which implies about 20% upside from recent levels.","news_type":1,"symbols_score_info":{"NFLX":0.9}},"isVote":1,"tweetType":1,"viewCount":969,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362083910,"gmtCreate":1614573912630,"gmtModify":1704772576481,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/362083910","repostId":"2116168580","repostType":4,"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353445116,"gmtCreate":1616517085035,"gmtModify":1704795238950,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here","listText":"Comment here","text":"Comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/353445116","repostId":"1176257801","repostType":4,"repost":{"id":"1176257801","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616512273,"share":"https://ttm.financial/m/news/1176257801?lang=en_US&edition=fundamental","pubTime":"2021-03-23 23:11","market":"us","language":"en","title":"AstraZeneca to publish full trial data after U.S. rebuke","url":"https://stock-news.laohu8.com/highlight/detail?id=1176257801","media":"Reuters","summary":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours a","content":"<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to publish full trial data after U.S. rebuke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to publish full trial data after U.S. rebuke\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-23 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176257801","content_text":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.\nThe rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.\nAstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.\nThe Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.\nIts shares were down 2.5% in London trading.\nThe U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.\nAnthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.\n“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.\n“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”\n‘NEGATIVE REPORTS’\nBesides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.\nThe new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.\n“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.\nRival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.\nThe panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.\nAstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.\nLater analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.\nCONFIDENCE HIT\nConfidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.\nThe European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.\nThe latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.\nAnalysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.\nStephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.\n“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”\nThe AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.\nIt has been granted conditional marketing or emergency use authorization in more than 70 countries.\nMany countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.","news_type":1,"symbols_score_info":{"AZN.UK":0.9,"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323299614,"gmtCreate":1615342393938,"gmtModify":1704781403557,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323299614","repostId":"1102807948","repostType":4,"isVote":1,"tweetType":1,"viewCount":1019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096176622,"gmtCreate":1644341299934,"gmtModify":1676533914682,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096176622","repostId":"1153281093","repostType":4,"repost":{"id":"1153281093","kind":"news","pubTimestamp":1644333754,"share":"https://ttm.financial/m/news/1153281093?lang=en_US&edition=fundamental","pubTime":"2022-02-08 23:22","market":"us","language":"en","title":"7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1153281093","media":"InvestorPlace","summary":"Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out ","content":"<div>\n<p>Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out ...</p>\n\n<a href=\"https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Best Blue-Chip Stocks to Buy for Safety in This Volatile Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-08 23:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out ...</p>\n\n<a href=\"https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚","AAPL":"苹果","LMT":"洛克希德马丁","PFE":"辉瑞","WMT":"沃尔玛","INTC":"英特尔","COST":"好市多"},"source_url":"https://investorplace.com/2022/02/7-best-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153281093","content_text":"Blue-chip stocks present a unique opportunity in volitile markets, and we volatility seems to be the watchword for the start of the year.The stock market took a hammering in January, which turned out to be theworst start to the yearin over a decade. The incredible volatility in the market is attributable to multiple macro-economic factors, which have investors scrambling to safe-haven investments. Hence, it’s best to add a few blue-chip stocks to your portfolio to minimize risks.Investors are caught amid a perfect storm in the stock market. The Fed’s hawkish policies, the rising inflation, geopolitical tensions, and the pandemic’s grip over the world have pulverized market returns. Moreover, the Cboe Volatility Index is up over 70% year-to-date.Hence, in the current scenario, it’s best to bet on blue-chip stocks with a long track record of top and bottom-line growth. Additionally, these companies also have strong track records of growing shareholder rewards despite the challenges presented by the market.Let’s now look at seven of the most attractive blue-chip stocks to buy at this time.Apple Walmart Exxon Mobil Pfizer Intel Corporation Costco Wholesale Lockheed Martin Apple Source: dennizn / Shutterstock.comApple has had a phenomenal run in the past couple of years,crossing $3 trillion in market capitalizationlast month.Despite the challenges, AAPL stock has generated solid returns over the past year, driven by staggering growth across all its business segments. The iPhone market boasts a most innovative product lineup with a loyal customer base.The free cash flow juggernaut boasts a levered FCF growth of 20%. Its cash flow expansion rate is stunning and will continue to grow with its top-line. Revenue growth is over 28.5% on a year-over-year basis, comfortably ahead of its 5-year average.Apple has done incredibly well to leverage several secular megatrends, including 5G, the metaverse, streaming, EVs, and whatnot. Hence, if there’s one blue-chip to buy, you’d want to invest in AAPL.Walmart Source: fotomak / Shutterstock.comWalmart has proven time and being that it’s the template for its sector.The retail giant has dominated the brick-and-mortar sector and has significantly expanded its eCommerce wing. Though the pandemic has slightly altered its growth trajectory, its long-term case remains firmly intact.During the first nine months of fiscal 2022, Walmart’s $416 billion sales increased by 3% compared with the prior-year period. However, its net income slid 35%.Nevertheless, it projects optimism and expects a 6% growth in comparable sales for the year. It has also raised earnings guidancefor the year by 20 cents to $6.40 per share.Looking ahead, the company will continue improving its eCommerce productivity and return to winning ways with its brick-and-mortar business.Exxon Mobil Source: Jonathan Weiss / Shutterstock.comExxon Mobil grew its earnings at an astounding pace last year. Year-over-year growth in its EBITDA is at a spectacular 75%.The oil and gas giant also is ramping up capital expenditure to explore a clean energy future and offers an attractive 4.37% dividend yield with remarkable consistency.Exxon Mobil saw a massive improvement in its top-line due to the robust crude oil prices last year. Revenues grew at a rapid clip while it managed to reduce debt levels by a colossal $20 billion.It improved its breakdown significantly by getting a better handle on costs. Additionally, it could spend a truckload of cash on expanding its low carbon efforts.With an impressive asset portfolio, outstanding financials and a tremendous outlook ahead, XOM stock is in a fantastic position to grow for the foreseeable future.Pfizer Source: photobyphm / Shutterstock.comPharmaceutical giant Pfizer has raked in billions from coronavirus vaccines sales, and its vaccines continue to be in high demand with the emergence of new variants of the virus.Vaccine salescontributed $36 billionin sales last year, doubling revenues for the company from 2020.Pfizer has demonstrated superb execution and scaling capacity, making it a top vaccine manufacturer in the west.Moreover, the pandemic is expected to be endemic, and the vaccine maker can still rake in plenty of moolah for the foreseeable future.It is also developing new products such as an oral antiviral tablet to treat early-stage Covid 19 symptoms. Hence, PFE stock still has a strong growth runway ahead.Intel Corporation Intel is one of the most powerful tech giants globally, with a market cap of over $180 billion.It is a household name in the semi-conductor space possessing superior manufacturing capabilities. In recent years, though, it has ceded a considerable amount of market share to its peers.It now looks as if Intel has a clear road to claw back its market share and expand into other profitable verticals.As we advance, the company will be looking to source some of its components from TSMC(NYSE:TSM) in speeding up chip development.It also plans to set up its personal chip foundry service, and its acquisition of autonomousdriving solutions provider Mobileyecould potentially unlock $50 billion in value.Also, Intel has the organic resources to pursue its developments plans, as it continues to generate unbelievable cash flows.Costco Wholesale Source: ARTYOORAN / Shutterstock.comRetail giant Costco has been one of the most consistent performers in its sector.Last year, the company grew its top and bottom lines by double-digits by 17.5% and 25.1%, respectively.With its water-tight balance sheet and unique competitive advantages, COST stock has been one of the top growth stocks over the years.Costco added 22 new warehouses to expand its outreach and more than 6 million new membersto its subscription service, with a roughly 92% renewal rate.Though its membership fees represent a small portion of sales, they contribute immensely to expanding profitability margins.The ability to offer low prices fuels membership growth. Hence, there’s plenty to love about COST stock as a long-term bet.Lockheed Martin Source: Ken Wolter / Shutterstock.comLockheed Martin is the leading defense contractor for the United States government.It has become a juggernaut in the space by being a provider of the F-35 JSF program.The company has been a robust performer with double-digit average revenue growth over the past five years while generating a monstrous 53% return during the same period.Last year,the company delivered 142 F-35 jetsto its customers, beating its previous guidance of 139 deliveries. Moreover, it expects to nail its production goal of 151-153 jets next year. The stellar performance has led to a healthy increase in its FCF margin to 7.3%. On top of that, it’s maintained its reputation as a top income stock in the space, with a 2.9% yield and a payout ratio of over 35%.","news_type":1,"symbols_score_info":{"WMT":0.9,"AAPL":0.9,"INTC":0.9,"XOM":0.9,"COST":0.9,"LMT":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340899729,"gmtCreate":1617367717561,"gmtModify":1704699228238,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Down more","listText":"Down more","text":"Down more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/340899729","repostId":"2124875875","repostType":4,"isVote":1,"tweetType":1,"viewCount":3591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353442734,"gmtCreate":1616517049328,"gmtModify":1704795237653,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/353442734","repostId":"1176257801","repostType":4,"repost":{"id":"1176257801","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616512273,"share":"https://ttm.financial/m/news/1176257801?lang=en_US&edition=fundamental","pubTime":"2021-03-23 23:11","market":"us","language":"en","title":"AstraZeneca to publish full trial data after U.S. rebuke","url":"https://stock-news.laohu8.com/highlight/detail?id=1176257801","media":"Reuters","summary":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours a","content":"<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to publish full trial data after U.S. rebuke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to publish full trial data after U.S. rebuke\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-23 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.</p>\n<p>The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.</p>\n<p>AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.</p>\n<p>The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.</p>\n<p>Its shares were down 2.5% in London trading.</p>\n<p>The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.</p>\n<p>Anthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.</p>\n<p>“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.</p>\n<p>“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”</p>\n<p>‘NEGATIVE REPORTS’</p>\n<p>Besides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.</p>\n<p>The new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.</p>\n<p>“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.</p>\n<p>Rival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.</p>\n<p>The panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.</p>\n<p>AstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.</p>\n<p>Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.</p>\n<p>CONFIDENCE HIT</p>\n<p>Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.</p>\n<p>The European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.</p>\n<p>The latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.</p>\n<p>Analysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.</p>\n<p>Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.</p>\n<p>“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”</p>\n<p>The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.</p>\n<p>It has been granted conditional marketing or emergency use authorization in more than 70 countries.</p>\n<p>Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176257801","content_text":"AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.\nThe rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.\nAstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.\nThe Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.\nIts shares were down 2.5% in London trading.\nThe U.S. National Institute for Allergy and Infectious Diseases (NIAID) said on Monday that the board charged with ensuring the trial’s accuracy had expressed concern the company may have given an incomplete view of the shot’s effectiveness.\nAnthony Fauci, director of the NIAID, said the whole issue was a really unfortunate unforced error.\n“This is very likely a very good vaccine and this kind of thing does ... nothing but really cast some doubt about the vaccines and may contribute to the hesitancy,” he told “Good Morning America” on ABC News.\n“The data really are quite good but when they put it into the press release it wasn’t completely accurate,” he said. “We have to keep essentially trying as hard as we can to get people to understand that there are safeguards in place.”\n‘NEGATIVE REPORTS’\nBesides being 79% effective in stopping symptomatic illness in the trial in the United States, Chile and Peru, the data also showed the shot was 100% effective against severe or critical forms of the disease and posed no increased risk of blood clots.\nThe new doubts about the shot’s efficacy, however, coincide with its rollout in dozens of countries and clouds the timeline for its emergency use authorization in the United States.\n“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.\nRival vaccines from Pfizer/BioNTech and Moderna that use so-called mRNA technology produced efficacy rates of about 95% each, far above the 50% benchmark set by global regulators.\nThe panel monitoring the AstraZeneca trial, the Data and Safety Monitoring Board, is organized by NIAID and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study.\nAstraZeneca’s COVID-19 shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing mistake.\nLater analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.\nCONFIDENCE HIT\nConfidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.\nThe European Union’s drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained skeptical about its safety.\nThe latest trial data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.\nAnalysts had noted AstraZeneca’s achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.\nStephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent cases, which may include new variants and thus lower protection rates.\n“The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case.”\nThe AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.\nIt has been granted conditional marketing or emergency use authorization in more than 70 countries.\nMany countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea’s President Moon Jae-in who received it on Tuesday.","news_type":1,"symbols_score_info":{"AZN.UK":0.9,"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3099,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321797500,"gmtCreate":1615468933700,"gmtModify":1704783168051,"author":{"id":"3567067505165206","authorId":"3567067505165206","name":"JohnHo","avatar":"https://static.tigerbbs.com/4ed2ebf7f0fdc4fd1f4def8d374111cc","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3567067505165206","idStr":"3567067505165206"},"themes":[],"htmlText":"Comment here","listText":"Comment here","text":"Comment here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/321797500","repostId":"1185608276","repostType":4,"repost":{"id":"1185608276","kind":"news","pubTimestamp":1615463354,"share":"https://ttm.financial/m/news/1185608276?lang=en_US&edition=fundamental","pubTime":"2021-03-11 19:49","market":"us","language":"en","title":"Cathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1185608276","media":"The Wall Street Journal","summary":"Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead\nMore t","content":"<p>Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead</p>\n<p>More than half the companies in Cathie Wood’s five popular exchange-traded funds at ARK Investment Management LLC were unprofitable in their latest year, a characteristic that analysts say will likely add to the volatility in these funds in the coming months.</p>\n<p>Of the 165 stocks included in ARK’s actively managed ETFs, 85 generated net losses in their latest fiscal years, according to an analysis by Dow Jones Market Data. That made the funds&nbsp;particularly vulnerable to dramatic swings&nbsp;when investors turned their backs on growth stocks in favor of shares that shine when the economy prospers.</p>\n<p>Despite&nbsp;this week’s rebound in tech stocks, all five of ARK’s ETFs remain down at least 18% from their mid-February highs, trailing the Nasdaq Composite, which is off 7.3% from its Feb. 12 record.</p>\n<p>The pain has been most acute among shares of the unprofitable companies in ARK’s funds. Those stocks have fallen on average 23% over the past month, according to a DJMD analysis of ARK’s holdings and FactSet data, while the profitable holdings are down 10% over the same period.</p>\n<p>“These stocks are inherently more risky than the broader market,” said Ben Johnson, director of global ETF research at Morningstar.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Finds Gains and Pain in Money-Losing Companies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-11 19:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/cathie-woods-ark-finds-gains-and-pain-in-money-losing-companies-11615458601?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead\nMore than half the companies in Cathie Wood’s five popular exchange-traded funds at ARK Investment ...</p>\n\n<a href=\"https://www.wsj.com/articles/cathie-woods-ark-finds-gains-and-pain-in-money-losing-companies-11615458601?mod=hp_lead_pos3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKF":"ARK Fintech Innovation ETF","ARKK":"ARK Innovation ETF"},"source_url":"https://www.wsj.com/articles/cathie-woods-ark-finds-gains-and-pain-in-money-losing-companies-11615458601?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185608276","content_text":"Heavily invested in unprofitable companies, the firm’s ETFs likely face more volatility ahead\nMore than half the companies in Cathie Wood’s five popular exchange-traded funds at ARK Investment Management LLC were unprofitable in their latest year, a characteristic that analysts say will likely add to the volatility in these funds in the coming months.\nOf the 165 stocks included in ARK’s actively managed ETFs, 85 generated net losses in their latest fiscal years, according to an analysis by Dow Jones Market Data. That made the funds particularly vulnerable to dramatic swings when investors turned their backs on growth stocks in favor of shares that shine when the economy prospers.\nDespite this week’s rebound in tech stocks, all five of ARK’s ETFs remain down at least 18% from their mid-February highs, trailing the Nasdaq Composite, which is off 7.3% from its Feb. 12 record.\nThe pain has been most acute among shares of the unprofitable companies in ARK’s funds. Those stocks have fallen on average 23% over the past month, according to a DJMD analysis of ARK’s holdings and FactSet data, while the profitable holdings are down 10% over the same period.\n“These stocks are inherently more risky than the broader market,” said Ben Johnson, director of global ETF research at Morningstar.","news_type":1,"symbols_score_info":{"ARKK":0.9,"ARKF":0.9}},"isVote":1,"tweetType":1,"viewCount":1218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}